Silverarc Capital Management LLC Has $5.19 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Silverarc Capital Management LLC raised its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 612,173 shares of the specialty pharmaceutical company’s stock after acquiring an additional 37,615 shares during the quarter. Silverarc Capital Management LLC owned about 1.24% of KalVista Pharmaceuticals worth $5,185,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. State Street Corp increased its holdings in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after purchasing an additional 515,179 shares in the last quarter. Schroder Investment Management Group grew its stake in KalVista Pharmaceuticals by 86.8% in the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after acquiring an additional 374,213 shares during the period. Walleye Capital LLC bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $2,268,000. Vanguard Group Inc. raised its holdings in KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock worth $19,102,000 after buying an additional 104,716 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of KalVista Pharmaceuticals by 691.5% during the fourth quarter. Marshall Wace LLP now owns 117,978 shares of the specialty pharmaceutical company’s stock worth $999,000 after acquiring an additional 103,072 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have commented on KALV. Jones Trading reissued a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, JMP Securities started coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $12.01 on Tuesday. The company has a market cap of $597.09 million, a P/E ratio of -3.30 and a beta of 0.39. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $15.50. The stock’s fifty day moving average price is $11.38 and its two-hundred day moving average price is $10.31.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was purchased at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the transaction, the insider now owns 4,986,480 shares in the company, valued at $43,681,564.80. The trade was a 0.88 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now directly owns 278,855 shares in the company, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders purchased 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).